74 related articles for article (PubMed ID: 11501330)
1. Proactive safety surveillance.
Bortnichak EA; Wise RP; Salive ME; Tilson HH
Pharmacoepidemiol Drug Saf; 2001 May; 10(3):191-6. PubMed ID: 11501330
[TBL] [Abstract][Full Text] [Related]
2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
4. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing surveillance: perspectives of a journal editor.
Gelenberg AJ
Psychopharmacol Bull; 1993; 29(1):135-7. PubMed ID: 8378507
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological approaches to safety investigations.
Wood JL; Adams VJ
Vet Microbiol; 2006 Oct; 117(1):66-70. PubMed ID: 16713135
[TBL] [Abstract][Full Text] [Related]
8. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
Murphy S; Roberts R
J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
[TBL] [Abstract][Full Text] [Related]
9. The role of scientific evidence of risks and benefits in determining risk management policies for medications.
Andrews E; Dombeck M
Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):599-608. PubMed ID: 15362082
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
[TBL] [Abstract][Full Text] [Related]
11. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
12. Precautions for proactive surveillance.
Walker AM; Wise RP
Pharmacoepidemiol Drug Saf; 2002; 11(1):17-20. PubMed ID: 11998546
[TBL] [Abstract][Full Text] [Related]
13. Leavitt: reforms will improve oversight and openness at FDA.
FDA Consum; 2005; 39(3):37. PubMed ID: 16127819
[TBL] [Abstract][Full Text] [Related]
14. Contributing to drug safety.
Johnson JM
Am J Hosp Pharm; 1990 Jun; 47(6):1280. PubMed ID: 2368721
[No Abstract] [Full Text] [Related]
15. Active drug safety surveillance: a tool to improve public health.
Platt R; Madre L; Reynolds R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1175-82. PubMed ID: 18823068
[TBL] [Abstract][Full Text] [Related]
16. The drug safety review process.
Somberg J
Am J Ther; 2007; 14(2):119. PubMed ID: 17414577
[No Abstract] [Full Text] [Related]
17. Metabolites and safety: What are the concerns, and how should we address them?
Smith DA; Obach RS
Chem Res Toxicol; 2006 Dec; 19(12):1570-9. PubMed ID: 17173370
[TBL] [Abstract][Full Text] [Related]
18. Short patent lives jeopardize drug and patient safety.
Hondeghem LM; De Clerck F; Camm J
J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
[TBL] [Abstract][Full Text] [Related]
19. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
20. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
[Next] [New Search]
